|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market
GBI Research, Sep 2011, Pages: 142
GBI Research, the leading business intelligence provider, has released its latest research, “Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market”, which provides insights regarding therapeutic proteins sales forecasts until 2017. Therapeutic proteins markets in the key geographies of the US, the top five EU countries, and Japan are also covered in the report. The report also includes details about therapeutic proteins R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of the main therapeutic protein classes, which includes monoclonal antibodies, insulins, interferons, growth hormones, colony stimulating factors, erythropoietins and blood factors. Furthermore, it includes market forecasts for each therapeutic class. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.
GBI Research’s analysis estimated the global therapeutic proteins market to be valued at $93billion in 2010, with a compound annual growth rate (CAGR) of 16.4% between 2002 and 2010. The market is forecast to grow at a CAGR of 6.2% between 2010 and 2017, to reach $141.5 billion in 2017. In-depth analysis in the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.
GBI Research’s analysis found the R&D pipeline for the therapeutic proteins market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that therapeutic proteins R&D activity will remain active for at least the next four to five years.
Scope
- The report analyzes market characterization, pipeline analysis and the competitive landscape in the therapeutic proteins market.
- Data and analysis of the therapeutic proteins market in the leading geographies of the world: the US, Europe and Rest of the World.
- Annualized market data for the therapeutic proteins market from 2002 to 2010, with forecasts to 2017 for blood factors, colony stimulating factors, erythropoietins, human growth hormone, insulin, interferons and monoclonal antibodies.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes.
- Key drivers and restraints that have had a significant impact on the market.
- Competitive landscape of the global therapeutic proteins market, including benchmarking of the top companies. The key companies studied in this report are Pfizer, Merck/Schering-Plough, F. Hoffmann-La Roche, Eli Lilly, Sanofi, Johnson and Johnson, Novo Nordisk, Amgen, Biogen and Abbott.
Reasons to buy
The report will aid business development and help marketing executives strategizing product launches -
- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.'
|
|
|
|
